Antifimgal agents. part ii. the azoles

Mayo Clinic Proceedings

Volumn 74, Issue 1, 1999, Pages 78-100

  Terrell, Christine L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CISAPRIDE; CYCLOSPORIN; DIDANOSINE; DIGOXIN; FELODIPINE; FLUCONAZOLE; FLUCYTOSINE; HYDROCHLOROTHIAZIDE; IMIDAZOLE DERIVATIVE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; MICONAZOLE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; POTASSIUM IODIDE; RIFABUTIN; RIFAMPICIN; TACROLIMUS; THEOPHYLLINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; WARFARIN; ZIDOVUDINE;

ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDIASIS; COCCIDIOIDOMYCOSIS; CONFERENCE PAPER; CRYPTOCOCCOSIS; DRUG CHOICE; DRUG COST; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; EDEMA; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; HISTOPLASMOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MYCOSIS; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; SEXUAL DYSFUNCTION; SKIN TOXICITY; SPOROTRICHOSIS;

EID: 0032895608     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.1.78     Document Type: Article

References (264)

1. Van den Bossche H, Willemsens G, Cools W, Cornelissen F, Lauwers WF, van Cutsem JM. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980; 17:922-928
2. Van Der Meer JWM, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole [letter]. J Antimicrob Chemother 1980;6:552-554
3. Lake-Bakaar G, Tom W, Lake-Bakaar D, Gupta N, Beidas S, Elsakr M, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;109:471-473
4. Knapp MJ, Berardi RR, Dressman JB, Rider JM, Carver PL. Modification of gastric pH with oral glutamic acid hydrochloride. Clin Pharm 1991:10:866-869
5. Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (CocaCola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995:39:1671-1675
6. Bennett JE. Antifungal agents. In: Mandell GL, Douglas RG Jr, Bennett JE, editors. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone; 1990. pp 361-370
7. Carver PL, Berardi RR, Rider JM, Knapp MJ, Kauffman CA. Interaction of ketoconazole and sucralfate in healthy volunteers [abstract]. Pharmacotherapy 1991;11:101
8. Andrews FA, Peterson LR, Beggs WH, Crankshaw D, Sarosi GA. Liquid Chromatographie assay of ketoconazole. Antimicrob Agents Chemother 1981:19:110-113
9. Graybill JR, Lundberg D, Donovan W, Levine HB, Rodriguez MD, Drutz DJ. Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients. Rev Infect Dis 1980:2:661-673
10. Sugar AM, Alsip SG, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31:1874-1878
11. Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother 1982;21:151-158
12. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, A very GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23:l-36
13. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985:103:861-872
14. Slama TG. Treatment of disseminated and progressive cavitary histoplasmosis with ketoconazole. Am J Med 1983;74(Suppl lB):70-73
15. Wheat LJ, Connolly-Stringfield PA, Baker RL, Curfman MF, Eads ME, Israel KS, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine 1990;69:361-374
16. Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med 1985:103:872-879
17. Saag MS, Dismukes WE. Treatment of histoplasmosis and blastomycosis. Chest 1988;93:848-851
18. Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis-a prospective study of 12 cases. Am J Gastroenterol 1983:78:261-264
19. Symoens J, Moens M, Dom J, Scheijgrond H, Dony J, Schuermans V, et al. An evaluation of two years of clinical experience with ketoconazole. Rev Infect Dis 1980:2:674-687
20. Drouhet E, Dupont B. Chronic mucocutaneous candidosis and other superficial and systemic mycoses successfully treated with ketoconazole. Rev Infect Dis 1980;2:606-619
21. Laguna F, Rodriguez-Tudela JL, Martinez-Suarez JV, Polo R, Valencia E, Diaz-Guerra TM, et al. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis 1997;24:124-130
22. Galgiani JN, Stevens DA, Graybill JR, Dismukes WE, Cloud GA (NIAID Mycoses Study Group). Ketoconazole therapy of progressive coccidioidomycosis: comparison of 400- and 800-mg doses and observations at higher doses. Am J Med 1988:84:603-610
23. Negroni R, Robles AM, Arechavala A, Tuculet MA, Galimberti R. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. Rev Infect Dis 1980;2:643-649
24. Restrepo A, Gomez I, Cano LE, Arango MD, Gutiérrez F, Sanin A, et al. Treatment of paracoccidioidomycosis with ketoconazole: a threeyear experience. Am J Med 1983;74(Suppl lB):48-52
25. RobledoMA, Gomez I, GutierrezF, etal. Evaluacion a largo plazo de pacientes con paracoccidioidomycosis tratados con ketoconazol. Acta Med Colombian/ 1985;10:155-160
26. Galgiani JN, Stevens DA, Graybill JR, Stevens DL, Tillinghast AJ, Levine HB. Pseudallescheria boydii infections treated with ketoconazole: clinical evaluations of seven patients and in vitro susceptibility results. Chest 1984;86:219-224
27. Dismukes WE, Stamm AM, Graybill JR, Craven PC, Stevens DA, Stiller RL, et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients; National Institute of Allergy and Infectious Diseases Collaborative Antifungal Study. Ann Intern Med 1983;98:13-20
28. Calhoun DL, Waskin H, White MP, Bonner JR, Mulholland JH, Rumans LW, et al. Treatment of systemic sporotrichosis with ketoconazole. Rev Infect Dis 1991;13:47-51
29. Perfect JR, Durack DT, Hamilton JD, Gallis HA. Failure of ketoconazole in cryptococcal meningitis. JAMA 1982:247:33493351
30. Drouhet E, Dupont B. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am J Med 1983;74(Suppl lB):30-47
31. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984;86:503-513
32. Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994; 28:1177-1181
33. Pont A, Williams PL, Loose DS, Feldman D, Bochra C, Reitz RE, et al. Ketoconazole inhibits adrenal steroid synthesis [abstract]. Clin Res 1982;30:520A
34. Pont A, Williams PL, Loose DS, Feldman D, Reitz RE, Bochra C, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982:97:370-372
35. Leal-Cerro A, Garcfa-Luna PP, Villar J, Miranda ML, Pereira JL, Gomez-Pan A, et al. Arterial hypertension as a complication of prolonged ketoconazole treatment. J Hypertens 1989;7(Suppl 6):S212-S213
36. Safety of antimicrobial drugs in pregnancy. Med Lett Drug Ther 1987:29:61-63
37. White DJG, Blatchford NR, Cauwenbergh G. Cyclosporine and ketoconazole. Transplantation 1984;37:214-215
38. Smith AF. Potentiation of oral anticoagulants by ketoconazole. BMJ 1984;288:188-189
39. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 1986:39:654-659
40. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994:55:481-485
41. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994:56:601-607
42. Xanax (brand of alprazolam tablets, USP) [package insert]. Kalamazoo (Ml): Pharmacia & Upjohn Company; 1996
43. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990:264:2788-2790
44. Blum RA, D'Andréa DT, Florentine BM, Wilton JH, Hilligoss DM, Gardner MJ, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991:114:755-757
45. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influ ence of concomitant food intake on the oral absorption of twotriazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994;46:147-150
46. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12(Suppl 3):S318-S326
47. De Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;l:746-748
48. Bozzette SA, Gordon RL, Yen A, Rinaldi M, Ito MK, Fierer J. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin Infect Dis 1992;15:701-703
49. Thaler F, Bernard B, Tod M, Jedynak CP, Petitjean O, Derome P, et al. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother 1995:39:1154-1156
50. Finley RW, Cleary JD, Goolsby J, Chapman SW. Fluconazole penetration into the human prostate. Antimicrob Agents Chemother 1995:39:553-555
51. Koks CHW, Meenhorst PL, Hillebrand MJX, Bult A, Beijnen JH. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob Agents Chemother 1996;40:1935-1937
52. Tucker RM, Williams PL, Arathoon EG, Levine BE, Hartstein AI, Hanson LH, et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother 1988:32:369-373
53. Arndt CAS, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988:157:178-180
54. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985:28:648-653
55. Graybill JR. New antifungal agents, fur J Clin Microbiol Infect Dis 1989:8:402-412
56. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Proposed Standard. Villanova (PA): NCCLS; 1995 (Publication No. NCCLS M27-T)
57. Rex JH, Pf aller MA, Galgiani JN, Bartlett MS, Espinel-lngroff A, Ghannoum MA, et al (Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards). Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-247
58. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996:34:489-495
59. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997:24:776-784
60. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990:34:2267-2268
61. Chave JP, Cajot A, Bille J, Glauser MP. Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study. J Infect Dis 1989:159:806-807
62. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virusinfected patients. J Infect Dis 1996:174:821-827
63. Revankar SG, Dib OP, Kirkpatrick WR, McAtee RK, Fothergilt AW, Rinaldi MG, et al. Clinical evaluation and microbiology of fluconazole resistant oropharyngeal candidiasis [abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC), p 124
64. Leen CLS, Dunbar EM, Ellis ME, Mandai BK. Once weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990:21:55-60
65. Willocks L, Leen CLS, Brettle RP, Urquhart D, Russell TB, Milne UR. Fluconazole resistance in AIDS patients [letter]. J Antimicrob Chemother 1991:28:937-939
66. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995:39:1-8
67. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219-225
68. Vuffray A, Durasse! C, Boerlin P, Boerlin-Petzold F, Bille J, Glauser MP, et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients [letter]. AIDS 1994;8:708-709
69. Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets [letter]. Ann Intern Med 1997;126:332-333
70. Laine L, Dretler RH, Conteas CN, Tuazon C, Koster FM, Sattler F, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992:117:655-660
71. Lake-Lewin D, Kunzweiler J, Buell DN. Fluconazole (FLU) vs amphotericin B (AMB) treatment of esophageal candidiasis in adults with malignancy [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1990:30:299
72. Brammer KW, Feczko JM. Single-dose oral fluconazole in the treatment of vaginal candidosis. Ann N Y Acad Sei 1988:544:561563
73. Perry CM, Whittington R, McTavish D. Fluconazole: an update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis. Drugs 1995:49:984-1006
74. Hay RJ, Clayton YM. Fluconazole in the management of patients with chronic mucocutaneous candidosis [letter]. Br J Dermatol 1988:119:683-684
75. Levine J, Bernard DB, Idelson BA, Farnham H, Saunders C, Sugar AM. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med 1989:86:825-827
76. Hoch BS, Namboodiri NK, Banayat G, Neiderman G, Louis BM, Manohar NL, et al. The use of fluconazole in the management of Candida peritonitis in patients on peritoneal dialysis. Périt Dial Int 1993;13(Suppl 2):S357-S359
77. Chan TM, Chan CY, Cheng SW, Lo WK, Lo CY, Cheng IK. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients. Nephrol Dial Transplant 1994:9:539-542
78. Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995:119:477-481
79. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995:20:657-664
80. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997:25:43-59
81. Voss A, Meis JFGM, Hoogkamp-Korstanje JAA. Fluconazole in the management of fungal urinary tract infections. Infection 1994:22:247-251
82. Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solutions for a budding problem. Clin Infect Dis 1995:20:183-189
83. Jacobs LG, Skidmore EA, Freeman K, Lipschultz D, Fox N. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996:22:30-35
84. Fan-Havard P, O'Donovan C, Smith SM, Oh J, Bamberger M, Eng RHK. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 1995:21:960-965
85. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991;91:137-141
86. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991:91:142-150
87. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-421
88. Edwards JE Jr. Should all patients with candidemia be treated with antifungal agents? [editorial]. Clin Infect Dis 1992;15:422-423
89. Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective observational study. Arch Intern Med 1995:155:2429-2435
90. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al (Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330
91. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun 0, Pinczowski H, Kontoyiannis DP, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996:101:170-176
92. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun 0, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996:23:964-972
93. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD (NIAID Mycoses Study Group and the Candidemia Study Group). Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995:39:40-44
94. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992:14:875-883
95. Uzun 0, Anaissie EJ. Problems and controversies in the management of hematogenous candidiasis. Clin Infect Dis 1996;22(Suppl 2):S95-S101
96. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991:325:1274-1277
97. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996:100:617-623
98. Kovacs JA, Kovacs AA, Polis M, Wright WC, Gill VJ, Tuazon CU, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985:103:533-538
99. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med 1986:104:234-240
100. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990:113:183-187
101. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al (NIAID Mycoses Study Group and the AIDS Clinical Trials Group). Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992:326:83-89
102. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group). Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15-21
103. de Lalla F, Pellizzer G, Vaglia A, Manfrin V, Franzetti M, Fabris P, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995:20:263-266
104. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994:19:741-745
105. Milefchik E, Leal M, Haubrich R, Bozzette S, Tilles J, Leedom J, et al. A phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis [abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC), p 65
106. Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22(Suppl 2):S119-S123
107. Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis 1996;22(Suppl 2):S148-S153
108. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al (NIAID AIDS Clinical Trials Group and the NIAID Mycoses Study Group). A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992:326:793-798
109. Pappas PG, Hamill RG, Kauffman CA, Bradsher RW, McKinsey DS, Cloud GW, et al (NIAID Mycoses Study Group). Treatment of cryptococcal meningitis in non-HIV infected patients-a randomized comparative trial [abstract]. In: Program and Abstracts of the Infectious Diseases Society of America 34th Annual Meeting; 1996 Sep 19-22; New Orleans, p 873
110. Dromer F, Mathoulin S, Dupont B, Brugiere 0, Letenneur L (French Cryptococcosis Study Group). Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin Infect Dis 1996;22(Suppl 2):S154-S160
111. Nelson MR, Fisher M, Cartledge J, Rogers T, Gazzard BG. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994;8:651-654
112. Meyohas MC, Roux P, Bollens D, Chouaid C, Rozenbaum W, Meynard JL, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 1995:21:628-633
113. Galgiani JN, Catanzaro A, Cloud GA, Higgs J, Friedman BA, Larsen RA, et al (NIAID-Mycoses Study Group). Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993:119:28-35
114. Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996;124:305-310
115. Perez JA Jr, Johnson RH, Caldwell JW, Arsura EL, Nemecheck P. Fluconazole therapy in coccidioidal meningitis maintained with intrathecal amphotericin B. Arch Intern Med 1995:155:1665-1668
116. Catanzaro A, Galgiani JN, Levine BE, Sharkey-Mathis PK, Fierer J, Stevens DA, et al (NIAID Mycoses Study Group). Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995:98:249-256
117. Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, et al (National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group). Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med 1997:103:223-232
118. Wheat J, Hafner R, Wulfsohn M, Spencer P, Squires K, Powderly W, et al (National Institute of Allergy and Infectious Diseases Clinical Trials and Mycoses Study Group Collaborators). Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993:118:610-616
119. Hecht F, Korzun A, Wheat J, Hafner R (NIH AIDS Clinical Trial Group). Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1995;35:241
120. Diaz M, Negroni R, Montero-Gei F, Castro LG, Sampaio SA, Borelli D, et al (Pan-American Study Group). A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin Infect Dis 1992;14(Suppl 1):S68-S76
121. McKinsey DS, Kauffman CA, Pappas PG, Cloud GA, Girard WM, Sharkey PK, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group). Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996:23:996-1001
122. Negroni R, Robles AM, Arechavala A, Taborda A. Itraconazole in human histoplasmosis. Mycoses 1989:32:123-130
123. Dismukes WE, Bradsher RW Jr, Cloud GA, Kauffman CA, Chapman SW, George RB, et al (NIAID Mycoses Study Group). Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992:93:489-497
124. Pappas PG, Bradsher RW, Chapman SW, Kauffman CA, Dine A, Cloud GA, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group). Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995:20:267-271
125. Pappas PG, Bradsher RW, Kauffman CA, Cloud GA, Thomas CJ, Campbell GD Jr, et al (National Institute of Allergy and Infectious Diseases Mycoses Study Group). Treatment of blastomycosis with higher doses of fluconazole. Clin Infect Dis 1997:25:200-205
126. Kauffman CA, Pappas PG, McKinsey DS, Greenfield RA, Perfect JR, Cloud GA, et al (NIAID Mycoses Study Group). Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996:22:46-50
127. Sharkey-Mathis PK, Kauffman CA, Graybill JR, Stevens DA, Hosteller JS, Cloud G, et al (NIAID Mycoses Study Group). Treat-ment of sporotrichosis with itraconazole. Am J Med 1993;95:279285
128. Montero-Gei F, Stevens DA, Sues L, Melendez M. Fluconazole therapy in cutaneous and lymphangitic sporotrichosis [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1990;30:182
129. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol 1994;31(Suppl):S91-S102
130. Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992;15:781-787
131. Anaissie EJ, Kontoyiannis DP, Huis C, Vartivarian SE, Karl C, Prince RA, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599602
132. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851
133. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552
134. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y (Bone Marrow Transplantation Team). Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant 1994;14:919-924
135. Ellis ME, Clink H, Ernst P, Halim MA, Padmos A, Spence D, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994:13:3-11
136. Winston DJ, Pakrasi A, Busuttil RW. Fluconazole prophylaxis of fungal infections in liver transplant recipients: results of a placebocontrolled, double-blind trial [abstract]. Presented at the Ninth International Symposium on Infections in the Immunocompromised Host; 1996 Jun 23-26; Assisi (Italy)
137. Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrion VS, Barrios C, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996;174:583-588
138. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebocontrolled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503
139. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-1849
140. Powderly WG, Finkelstein DM, Feinberg J, Frame P, He W, van der Horst C, et al (NIAID AIDS Clinical Trials Group). A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-705
141. Singh N, Barnish MJ, Berman S, Bender BS, Wagener MM, Rinaldi MG, et al. Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of <100/mm3: demonstration of efficacy in a prospective, multicenter trial. Clin Infect Dis 1996:23:1282-1286
142. Manfred! R, Mastroianni A, Coronado 0V, Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997:157:64-69
143. Schuman P, Capps L, Peng G, Vazquez J, el-Sadr W, Goldman AI, et al (Terry Beim Community Programs for Clinical Research on AIDS). Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: a randomized, double-blind, placebocontrolled trial. Ann Intern Med 1997:126:689-696
144. Wheat LJ. Antifungal prophylaxis in AIDS: should it be the standard of care? AIDS Clin Care 1994;6:27-30
145. Clancy CJ, Berg J, Nguyen MH. Emergence of fluconazole resistance in C. neoformans: the hidden danger of primary fluconazole prophylaxis in HIV-infected patients [abstract]. In: Program and Abstracts of the Infectious Diseases Society of America 35th Annual Meeting; 1997 Sep 13-16; San Francisco, p 170
146. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21(Suppl 1):S32-S43
147. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990:39:877916
148. Diflucan (fluconazole) [package insert]. New York: Roerig-Pfizer; 1994
149. Pappas PG, Kauffman CA, Perfect J, Johnson PC, McKinsey DS, Bamberger DM, et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995;123:354-357
150. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996;22:336-340
151. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996; 124:573-576
152. Mitchell AS, Holland JT. Fluconazole and phenytoin: a predictable interaction. BMJ 1989;298:1315
153. Lazar JD, Wilner KD. Key drug interaction studies with fluconazole [abstract]. 1989 Aug 19-23; Vancouver, British Columbia (Canada)
154. Isalska BJ, Stanbridge TN. Fluconazole in the treatment of candidal prosthetic valve endocarditis. BMJ 1988;297:178-179
155. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(Suppl 3):S327-S333
156. Ehninger G, Jaschonek K, Schuler U, Krüger HU. Interaction of fluconazole with cyclosporin [letter]. Lancet 1989;2:104-105
157. Sugar AM, Saunders C, Idelson BA, Bernard DB. Interaction of fluconazole and cyclosporine [letter]. Ann Intern Med 1989;110:844
158. Collignon P, Hurley B, Mitchell D. Interaction of fluconazole with cyclosporin [letter]. Lancet 1989;1:1262
159. Sahai J, Gallicano K, Pakuts A, Cameron DW. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994;169:1103-1107
160. Doble N, Shaw R, Rowland-Hill C, Lush M, Warnock DW, Keal EE. Pharmacokinetic study of the interaction between rifampicin and ketoconazole. J Antimicrob Chemother 1988;21:633-635
161. Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994;31(Suppl):S87-S90
162. Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-784
163. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kühn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32:1310-1313
164. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe
165. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791800
166. Systemic antifungal drugs. Med Lett Drugs Ther 1996;38:10-12
167. Smith D, van de Velde V, Woestenborghs R, Gazzard BG. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992;44:618-619
168. Hardin J, Lange D, Heykants J, Ding C, Van de Velde V, Slusser C, et al. The effect of co-administration of a cola beverage on the bioavailability of itraconazole in AIDS patients [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1995;35:6
169. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994:330:263-272
170. Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother 1985:16:8186
171. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. /Mycoses 1989;32(Suppl l):67-87
172. Heykants J, Van Peer A, Lavrijsen K, Meuldermans W, Woestenborghs R, Cauwenbergh G. Pharmacokinetics of oral antifungals and their clinical implications. Br J Clin Pract Symp Suppl 1990;71:50-56
173. Walsh TJ, Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988:7:460-475
174. Sporanox (itraconazole capsules) [package insert]. Titusville (NJ): Janssen Pharmaceutica Inc.; 1996
175. Sporanox (itraconazole oral solution) [package insert]. Titusville (NJ): Janssen Pharmaceutica Inc.; 1997
176. Cauwenbergh G, De Doncker P, Stoops K, De Dier A-M, Goyvaerts H, Schuermans V. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis 1987;9(Suppl 1):S146-S152
177. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1996;23:305-313
178. Restrepo A, Robledo J, Gornez I, Tabares AM, Gutiérrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986;122:413-417
179. Conti Diaz IA, Civila E, Gezuele E, Lowinger M, Calegari L, Sanabria D, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992:35:153-156
180. Winn RE, Anderson J, Piper J, Aronson NE, Pluss J. Systemic sporotrichosis treated with itraconazole. Clin Infect Dis 1993;17:210-217
181. Baker JM, Goodpasture HC, Kuhns HR Jr, Rinaldi MG. Fungemia caused by an amphotericin B-resistant isolate of Sporothrix schenckii: successful treatment with itraconazole. Arch Pathol Lab Med 1989:113:1279-1281
182. Heller HM, Fuhrer J. Disseminated sporotrichosis in patients with AIDS: case report and review of the literature. AIDS 1991;5:12431246
183. Bolao F, Podzamczer D, Ventin M, Gudiol F. Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis. Eur J Clin Microbiol Infect Dis 1994;13:609612
184. Parker JD, Sarosi GA, Doto IL, Bailey RE, Tosh FE. Treatment of chronic pulmonary histoplasmosis: a National Communicable Disease Center Cooperative Mycoses Study. N Engl J Med 1970; 283:225-229
185. Wheat J. Histoplasmosis: recognition and treatment. Clin Infect Dis 1994;19(Suppl I):S19-S27
186. Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, et al (AIDS Clinical Trial Group). Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995;98:336-342
187. Lockwood WR, Allison F Jr, Batson BE, Busey JF. The treatment of North American blastomycosis: ten years' experience. Am Rev RespirDis 1969;100:314-320
188. Abernathy RS. Amphotericin therapy of North American blastomycosis. Antimicrob Agents Chemother 1966;6:208-211
189. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990:26:561-566
190. Klein BS, Vergeront JM, Weeks RJ, Kumar UN, Mathai G, Varkey B, et al. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med 1986:314:529-534
191. Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996;22(Suppl 2):S102-S111
192. Pappas PG, Threlkeld MG, Bedsole GD, Cleveland KO, Gelfand MS, Dismukes WE. Blastomycosis in immunocompromised patients. Medicine 1993;72:311-325
193. De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988;31:476-485
194. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23:607-614
195. Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996:71:25-30
196. Viviani MA, Tortorano AM, Langer M, Almaviva M, Negri C, Cristina S, et al. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 1989;18:151-165
197. Denning DW, Van Wye JE, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991:100:813-819
198. Germaud P, Tuchais E. Allergic bronchopulmonary aspergillosis treated with itraconazole [letter]. Chest 1995:107:883
199. Stevens DA, Lee JY, Schwartz HJ, Jerome D, Catanzaro AI (NIAID Mycoses Study Group). Randomized double-blind study of itraconazole (IZ) in allergic bronchopulmonary aspergillosis (ABPA) [abstract]. Program Abstr Intersci ConfAntimicrob Agents Chemother 1997;37:LB-32
200. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases [published erratum appears in Rev Infect Dis 1991;13:345]. Rev Infect Dis 1990:12:1147-1201
201. Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994;19(Suppl 1):S41-S48
202. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994:97:135-144
203. Vivian! MA, Tortorano AM, Pagano A, Vigevani GM, Gubertini G, Cristina S, et al. European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 1990:23:587-593
204. Thomas PA, Abraham DJ, Kalavathy CM, Rajasekaran J. Oral itraconazole therapy for mycotic keratitis. /Mycoses 1988:31:271-279
205. van't Wout JW, Novakova I, Verhagen CAM, Fibbe WE, de Pauw BE, van der Meer JWM. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991:22:45-52
206. Kreisel W, Kochling G, von Schilling C, Azemar M, Kurzweil B, Dolken G, et al. Therapy of invasive aspergillosis with itraconazole: improvement of therapeutic efficacy by early diagnosis. Mycoses 1991:34:385-394
207. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997:157:1857-1862
208. Sanchez C, Mauri E, Dalmau D, Quintana S, Aparicio A, Garau J. Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clin Infect Dis 1995:21:1485-1487
209. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989:149:2301-2308
210. de Gans J, Portegies P, Tiessens G, Eeftinck Schattenkerk JK, van Boxtel CJ, van Ketel RJ, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-190
211. Hostetler JS, Denning DW, Stevens DA. US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 1992;38(Suppl l):12-22
212. Chotmongkol V, Jitpimolmard S. Treatment of cryptococcal meningitis with combination itraconazole and flucytosine. J Med Assoc Thai 1994:77:253-256
213. Cauwenbergh G. Cryptococcal meningitis: the place of itraconazole. Mycoses 1993:36:221-228
214. Batungwanayo J, Taelman H, Bogaerts J, Alien S, Lucas S, Kagame A, et al. Pulmonary cryptococcosis associated with HIV-1 infection in Rwanda: a retrospective study of 37 cases. AIDS 1994:8:1271-1276
215. Tucker RM, Williams PL, Arathoon EG, Stevens DA. Treatment of mycoses with itraconazole. Ann N Y Acad Sei 1988:544:451-470
216. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA (NIAID Mycoses Study Group). Itraconazole treatment of coccidioidomycosis. Am J Med 1990:89:282-290
217. Diaz M, Puente R, de Hoyos LA, Cruz S. Itraconazole in the treatment of coccidioidomycosis. Chest 1991:100:682-684
218. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990:112:108-112
219. Blatchford NR. Treatment of oral candidosis with itraconazole: a review. J Am Acad Dermatol 1990:23:565-567
220. Stein GE, Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother 1993:37:89-92
221. Ruhnke M, Eigler A, Tonnagen l, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994:32:2092-2098
222. Phillips P, Zemcov J, Mahmood W, Montaner JS, Craib K, Clarke AM. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996:10:1369-1376
223. Fessel WJ, Merrill KW, Ward D, Moskovitz B, Benken C, Oleka N, et al. Itraconazole oral solution (IS) for the treatment of fluconazolerefractory oropharyngeal candidiasis (OC) in HIV-positive patients [abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC), p 124
224. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997;176:227-232
225. Coppola S, Angarano G, Montagna MT, Congedo P, Monno L, Bellisario A, et al. Efficacy of itraconazole in treating AIDS-associated infections due to Candida krusei. Eur J Epidemiol 1995:11:243-244
226. Negroni R, Palmier! 0, Koren F, Tiraboschi IN, Galimberti RL. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis 1987;9(Suppl 1):S47-S50
227. Restrepo A, Gomez I, Robledo J, Patino MM, Cano LE. Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report. Rev Infect Dis 1987;9(Suppl 1):S51-S56
228. Naranjo MS, Trujillo M, Munera Ml, Restrepo P, Gomez I, Restrepo A. Treatment of paracoccidioidomycosis with itraconazole. J Med VetMycol 1990;28:67-76
229. Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sei 1988;544:504-516
230. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 1987;9(Suppl 1):S57S63
231. Supparatpinyo K, Nelson KE, Merz WG, Breslin BJ, Cooper CR Jr, Kamwan C, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Pénicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993;37:24072411
232. Goldberg SL, Geha DJ, Marshall WF, Inwards DJ, Hoagland HC. Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. din Infect Dis 1993:16:803-805
233. Nomdedeu J, Brunet S, Martino R, Altes A, Ausina V, DomingoAlbos A. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report [letter]. Clin Infect Dis 1993:16:731-733
234. Stolk-Engelaar MVM, Cox NJM. Successful treatment of pulmonary pseudallescheriasis with itraconazole [letter]. Eur J Clin Microbiol Infect Dis 1993;12:142
235. Pether JVS, Jones W, Greatorex FB, Bunting W. Acute pyogenic Pseudallescheria boydii foot infection sequentially treated with miconazole and itraconazole [letter]. J Infect 1992:25:335-336
236. Piper JP, Golden J, Brown D, Broestler J. Successful treatment of Scedosporium apiospermum suppurative arthritis with itraconazole. Pediatr Infect Dis J 1990:9:674-675
237. Van den Enden E, Van Compel A, Stevens A, Vandeghinste N, Le Ray D, Gigase P, et al. Treatment of cutaneous leishmaniasis with oral itraconazole. IntJDermatol 1994:33:285-286
238. Berger TG, Heon V, King C, Schulze K, Conant MA. Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis [letter]. Arch Dermatol 1995;131:358-360
239. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32(Suppl 1):103-108
240. Thunnissen PL, Sizoo W, Hendriks WD. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med 1991;39:84-91
241. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-Korstanje MA, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hématologie malignancies and intensive chemotherapy: a double blind, placebo controlled study. Leuk Lymphoma 1993:11:353-358
242. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW. Itraconazole (IT) oral solution vs fluconazole (F) suspension for antifungal prophylaxis in neutropenic patients [ab-stract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1996:36:286
243. Del Favero A, Menichetti F, Micozzi A, Bucaneve G, De Beule K, Martine P. Antifungal prophylaxis in neutropenic pts (<1000/mmc) with haematologic malignancy: a double-blind trial to compare itraconazole oral solution (IDS) with placebo (PLA) [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother ±997-37:380
244. Cauwenbergh G, Legendre R, Blatchford N. Itraconazole, a novel oral antifungal: its efficacy and safety profile. Presented at the 8th Regional Conference of Dermatology; 1988 Jun 16-20; Bali (Indonesia)
245. Lavalle P, Suchil P, De Ovando F, Reynoso S. Itraconazole for deep mycoses: preliminary experience in Mexico. Rev Infect Dis 1987;9(Suppl 1):S64-S70
246. Hann SK, Kirn IB, Im S, Han KH, Park YK. Itraconazole induced acute hepatitis [letter]. BrJDermatol 1993;129:500-501
247. Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, Roldaan AC, van't Wout JW, Stricker BH. Hepatic injury associated with itraconazole [letter]. Lancet 1992;340:251-252
248. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, G ray bill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707-713
249. Van Cauteren H, Heykants J, De Coster R, Cauwenbergh G. Itraconazole: pharmacologie studies in animals and humans. Rev Infect Dis 1987;9(Suppl 1):S43-S46
250. Saag M, Bradsher R, Chapman S, Kauffman C, Girard W, Stevens D, et al (NIAID Mycoses Study Group). Itraconazole (I) therapy (Rx) for blastomycosis (B), histopiasmosis (H), and sporotrichosis (S) [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1988;28:210
251. Van Cauteren H, Coussement W, Vandenberghe J, Herin V, Vanparys P, Marsboom R. The toxicological properties of itraconazole. In: Fromtling RA, editor. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona (Spain): JR Prous Science Publishers; 1987. pp 263-271
252. Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993:95:445-446
253. Important safety information. Titusville(NJ): Janssen Pharmaceutica Inc.; 1995
254. Novâkovâ I, Donnelly P, de Witte T, de Pauw B, Boezeman J, Veltman G. Itraconazole and cyclosporin nephrotoxicity [letter]. Lancet 1987;2:920-921
255. Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ. Interaction of cyclosporin and itraconazole [letter]. Lancet 1987;2:282
256. Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327-329
257. Rex J. Itraconazole-digoxin interaction [letter]. Ann Intern Med 1992;116:525
258. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993;16:400-403
259. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter]. N Engt J Med 1995:333:664-665
260. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995;33:134-135
261. Lefort A, Launay 0, Carbon C. Uveitis associated with rifabutin prophylaxis and itraconazole therapy [letter]. Ann Intern Med 1996;125:939-940
262. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole [letter]. Clin Infect Dis 1994;18:266
263. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-174
264. Moreno F, Hardin TC, Rinaldi MG, Graybill JR. Itraconazole didanosine excipient interaction [letter]. JAMA 1993;269:1508